

CURRICULUM VITAE

NAME: Juan J. L. Lertora, M.D., Ph.D.

PLACE OF BIRTH: Corrientes, Argentina

CITIZENSHIP: United States of America

CURRENT ACADEMIC POSITIONS:

Interim Associate Executive Director for Basic Science
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, Louisiana 2019-present

Adjunct Professor
Department of Clinical Research
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, Louisiana 2017-present

Adjunct Professor
Department of Medicine
Clinical Research Training Program
Duke University School of Medicine
Durham, North Carolina 2007-present

IMMEDIATE PAST POSITION:

Senior Clinician 2006-2016
Director, Clinical Pharmacology Program
National Institutes of Health Clinical Center
Bethesda, Maryland
(Retired from federal employment on January 31, 2016)

EDUCATION:

Colegio Nacional "San Martin" Bachelor 1958-62
Corrientes, Argentina

National University of the Northeast, Faculty of Medicine M.D. 1963-70
Corrientes, Argentina

Tulane University Graduate School Ph.D. 1970-74
New Orleans, Louisiana Pharmacology

TRAINING:

National University of the Northeast Faculty of Medicine, Corrientes, Argentina Rotating Internship	1969-70
University of Iowa College of Medicine Iowa City, Iowa Postdoctoral Fellowship Clinical Pharmacology	1974-75
University of Connecticut School of Medicine Farmington, Connecticut Residency – Internal Medicine	1975-77

ACADEMIC APPOINTMENTS:

National University of the Northeast Faculty of Medicine - Corrientes, Argentina Teaching Assistant, Department of Anatomy	1964-65
Teaching Assistant, Department of Physiology	1965-68
Teaching Assistant, Department of Pharmacology	1968-69
Tulane University School of Medicine Department of Pharmacology Research Associate	1970-71
Adjunct Research Associate	1971-73
Research Associate	1973-74
University of Iowa College of Medicine Department of Medicine Fellow Associate	1974-75
University of Connecticut School of Medicine Department of Medicine Instructor	1976-77
Northwestern University Medical School Departments of Medicine and Pharmacology Assistant Professor	1977-81
The Graduate School Northwestern University Member, Graduate Faculty	1980-81

Curriculum Vitae
Juan J.L. Lertora, M.D., Ph.D.
Page 3

Tulane University School of Medicine
Departments of Medicine and Pharmacology
Associate Professor and Head
Section of Clinical Pharmacology

1981-88

The Graduate School Tulane University Member, Graduate Faculty	1984-2006
Tulane University School of Medicine Departments of Medicine and Pharmacology Professor and Head, Section of Clinical Pharmacology	1988-2006
Duke University School of Medicine Department of Medicine Adjunct Professor	2007-present
Louisiana State University Pennington Biomedical Research Center Adjunct Professor	2017-present

SPECIAL TEACHING APPOINTMENTS

Faculty, FAES Graduate School (NIH Campus) Foundation for the Advanced Education in Science Bethesda, Maryland	2007-2016
Faculty, Clinical Research Training Program Duke University School of Medicine Durham, North Carolina	2007-2016

HOSPITAL STAFF APPOINTMENTS:

Northwestern Memorial Hospital (Chicago) Adjunct Staff Associate Staff	1977-79 1979-80
Veterans Administration Lakeside Hospital (Chicago) Attending Staff	1978-80
Tulane Medical Center Hospital and Clinic (New Orleans) Active Staff Physician	1981-2006
Charity Hospital (New Orleans) Visiting Staff Physician	1981-2006
Veterans Administration Medical Center (New Orleans) Consulting Physician Staff Physician	1986-93 1993-2006

National Institutes of Health Clinical Center (Bethesda) Senior Clinician – Staff Physician	2006-2016
Pennington Biomedical Research Center (Baton Rouge) Adjunct Staff Physician	2017-present

SPECIALTY CERTIFICATION:

American Board of Internal Medicine	1978
American Board of Clinical Pharmacology	1991

LICENSED:

Connecticut, Illinois, Louisiana

SOCIETIES:

Fellow, American College of Physicians
Fellow, American College of Clinical Pharmacology
Fellow, Southern Society for Clinical Investigation
Member, American Society for Clinical Pharmacology and Therapeutics
Member, American Society for Pharmacology and Experimental Therapeutics
Member, Society for Clinical and Translational Science

SPECIALTY BOARDS:

Member, American Board of Clinical Pharmacology	1994-2000
---	-----------

AWARDS:

E. Billingham Award - Valedictorian Colegio Nacional "San Martin" Corrientes, Argentina	1963
Interamerican Editorial Prize - Best Student Third Year Medical Class - National University of the Northeast, Faculty of Medicine, Corrientes, Argentina	1966

Merck, Sharp and Dohme *International Fellowship in*

<i>Clinical Pharmacology</i>	1971-73
Pharmaceutical Manufacturers Association Foundation (now PhRMA Foundation) <i>Faculty Development Award in Clinical Pharmacology</i>	1978-81
Clinical Faculty Honor Roll Award for Excellence in Teaching - Owl Club - Tulane University School of Medicine	1989
Clinical Faculty Honor Roll Award for Excellence in Teaching - Owl Club - Tulane University School of Medicine	1992
“Top 10 Grants” Award – Tulane University Health Sciences Center	2003
Leveraging/Collaboration Award Food and Drug Administration	2005
NIH Clinical Center Director’s Award for Teaching/Training National Institutes of Health	2008
NIH Director’s <i>Ruth L. Kirschstein Mentoring Award</i> National Institutes of Health	2010
NIH Director’s Merit Award recognizing expert evaluation on Training for FDA regulated research at NIH (team award)	2011
U.S. FDA Advisory Committee Service Award Pharmaceutical Science and Clinical Pharmacology FDA/CDER	2011
NIH Clinical Center Director’s Award recognizing the Pharmacogenomics Testing Implementation Team (chaired by Dr. Lertora)	2012
PhRMA Foundation <i>Award in Excellence in Clinical Pharmacology</i>	2013
American Society for Clinical Pharmacology and Therapeutics <i>Henry W. Elliott Distinguished Service Award</i>	2014
Argentine Ministry of Science and Technology <i>Premio RAICES (Roots Award) for International Cooperation</i>	2014

INVITED LECTURES AND SYMPOSIA:

Pfizer Lecture in Clinical Pharmacology
Northwestern University Medical School (1984)
Topic: "Inotropic Actions of Antiarrhythmic Drugs"

3rd Annual Coast Conference of the Mississippi Osteopathic
Medical Association (April 13, 1984)
Topic: "Overview of Beta Blockers"

American College of Physicians Postgraduate Course -
7th Annual New Orleans Internal Medicine Board Review Course
New Orleans, LA (September 4, 1985)
Topic: "Overview of Clinical Pharmacology"

American College of Angiology, 32nd Annual Meeting
Hilton Head Island (November 14, 1985)
Symposium on N-Acetylprocainamide (NAPA)
Topic: "Hemodynamic and Inotropic Actions of NAPA"

University of Kansas Medical Center
Division of Clinical Pharmacology
Special Seminar (March 24, 1986)
Topic: "Clinical Pharmacology of Antiarrhythmic Drugs"

Louisiana Society of Hospital Pharmacists, 43rd Annual Meeting
New Orleans, LA (April 27, 1986)
Guest Speaker
Topic: "Bioavailability and the Question of Generic
Drug Substitution"

Pedi Lung II Course - Rational Drug Therapy in Pediatric
Pulmonary Diseases (May 3, 1986)
Section of Pulmonary Diseases, Department of Pediatrics,
Tulane Medical Center
Guest Speaker
Topic: "Drug Reactions and Interactions"

American College of Physicians Postgraduate Course -
8th Annual New Orleans Internal Medicine Board Review Course
New Orleans, LA (September 2, 1986)
Topic: "Overview of Clinical Pharmacology"

INVITED LECTURES AND SYMPOSIA: (cont'd)

Law and Medicine Series Postgraduate Course
Sponsored by Tulane Law School and Tulane Medical Center
New Orleans, LA (October 10, 1986)

Topic: "The Role of Monitoring Blood Drug Levels"

Interamerican Society for Clinical Pharmacology and Therapeutics
Symposium on "Centrally-Active Antihypertensive Drugs"
Buenos Aires, Argentina (November 23, 1986)

Topic: "Clinical Pharmacokinetics of Clonidine"

Symposium on "Antiarrhythmic Drugs"
(Co-Chairman with Dr. Mauricio Rosenbaum)
Buenos Aires, Argentina (November 27, 1986)

Topic: "Active Metabolites of Antiarrhythmic Drugs"

Postgraduate Course in Clinical Pharmacology for Latin-
American Scientists
(Co-Sponsored by Pan American Health Organization)
Buenos Aires, Argentina (November 29, 1986)

Topic: "Drug Interactions"

Symposium on "Drug-Induced Hypokalemia"
Sponsored by The Internal Medicine Group
New Orleans, LA (December 4, 1986)

Topic: "Hypokalemia and Cardiac Arrhythmias"

American College of Physicians
Postgraduate Course - 9th Annual
New Orleans Internal Medicine Board Review Course
New Orleans, LA (September 8, 1987)

Topic: "Overview of Clinical Pharmacology"

Pfizer Lecture in Clinical Pharmacology
LSU-Shreveport School of Medicine (1987)
Topic: "The Pharmacology of N-Acetylprocainamide
(NAPA) and Desethyl-N-Acetylprocainamide
(NAPADE)"

LSU School of Medicine
Merck Sharp and Dohme
Special Training Course for Hospital Representatives
New Orleans, LA (November 6, 1987)

Topic: "Clinical Pharmacology of Antiarrhythmic Drugs"

INVITED LECTURES AND SYMPOSIA: (cont'd)

University Medical Center
Las Vegas, Nevada
Medical Grand Rounds (November 6, 1987)
Topic: "Drug Level Monitoring: Rationale and Indications"

LSU-Shreveport School of Medicine
Department of Pharmacology
Special Seminar (December 16, 1987)
Topic: "Hepatic Drug Clearance"

LSU-Shreveport School of Medicine
Department of Pediatrics
Grand Rounds (December 17, 1987)
Topic: "Clinical Pharmacology of Antiviral Drugs in AIDS"

New Orleans Internal Medicine
Board Review Course - 10th Annual
New Orleans, LA (September 10, 1988)
Topic: "Overview of Clinical Pharmacology"

New Orleans Internal Medicine
Board Review Course - 11th Annual
New Orleans, LA (September 6, 1989)
Topic: "Overview of Clinical Pharmacology"

American Society for Clinical Pharmacology and Therapeutics
Symposium on "Future Direction for Antiarrhythmic Drug Use
and Development" (Chairman)
San Francisco, CA (March 22, 1990)
Topic: "Inotropic Actions of Antiarrhythmic Drugs"

National University of the Northeast
Faculty of Medicine, Department of Pharmacology
Corrientes, Argentina (August 14, 1990)
Topic: "Genetic Influences on Drug Metabolism"

National University of the Northeast
Faculty of Medicine, University Hospital
Corrientes, Argentina (August 16, 1990)
Topic: "Clinical Pharmacologic Studies in AIDS Therapy"

Cardiology Institute of Corrientes
Corrientes, Argentina (August 18, 1990)
Topic: "Pharmacologic Treatment of Cardiac Arrhythmias"

INVITED LECTURES AND SYMPOSIA: (cont'd)

New Orleans Internal Medicine Board Review Course - 12th Annual
New Orleans, LA (September 5, 1990)
Topic: "Overview of Clinical Pharmacology"

Royal College of Physicians of Ireland
Symposium on "Early Medical Intervention in HIV Infection"
Dublin, Ireland (November 30, 1990)
Panelist for Symposium Discussion

Royal College of Physicians of Ireland
Symposium on "The Place of Ribavirin in the Therapy of HIV
Infection" (Sponsored by ICN Pharmaceuticals)
Dublin, Ireland (December 1, 1990)
Topic: "Ribavirin Pharmacokinetics and Long-Term
Tolerance in HIV-Infected Patients"

Northwestern University Medical School
Department of Medicine
Clinical Pharmacology Center
Medical Grand Rounds (May 24, 1991)
Topic: "Clinical Pharmacology of Ribavirin in HIV Infection"

Xavier University of Louisiana
College of Pharmacy
New Orleans, LA (August 26, 1991)
Topic: "Drug Bioavailability and Generic Drug Substitution"

New Orleans Internal Medicine Board Review Course
13th Annual - New Orleans, LA (September 3, 1991)
Topic: "Overview of Clinical Pharmacology"

Southeastern Pharmacology Society
Symposium on "Advances in Hypertension and Cardiovascular Disease"
New Orleans, LA (November 9, 1991)
Topic: "The Negative Inotropic and Proarrhythmic
Action of Antiarrhythmic Drugs"

Louisiana State University School of Medicine in Shreveport
Department of Pharmacology
Seminar (February 18, 1992)
Topic: "Clinical Pharmacology of Ribavirin in
Patients with HIV Infection"

New Orleans Internal Medicine Board Review Course - 14th Annual
New Orleans, LA (September 8, 1992)
Topic: "Overview of Clinical Pharmacology"

INVITED LECTURES AND SYMPOSIA: (cont'd)

Xavier University of Louisiana
College of Pharmacy
Continuing Education Program
New Orleans, LA (April 25, 1993)
Topic: "Therapeutic and Bio-Equivalence of Drugs"

Hispanic American Medical Association
Primary Care Symposium II
New Orleans, LA (April 29, 1993)
Topic: "AIDS Update: New Antiretroviral Therapies"

Thibodaux General Hospital
CME Program
Thibodaux, LA (June 1, 1993)
Topic: "Drug Therapy of Cardiac Arrhythmias"

National University of the Northeast
Faculty of Medicine
Department of Pharmacology
Corrientes, Argentina (August 3, 1993)
Topic: "Clinical Trials in HIV Infection"

Argentine National Academy of Medicine
Buenos Aires, Argentina (August 6, 1993)
Topic: "Advances in Antiviral Therapy for HIV Infection"

New Orleans Internal Medicine Board Review Course
15th Annual
New Orleans, LA (September 7, 1993)
Topic: "Overview of Clinical Pharmacology"

Third International Medicine Course
Tulane University Medical Center
San Fernando Medical Center
Panama, Republic of Panama (September 16-18, 1993)
Topics: "Drug Therapy in Geriatrics"
"Pharmacologic Therapy of Cardiac Arrhythmias"
"Adverse Drug Reactions and Drug Interactions"

New Orleans Internal Medicine Board Review Course
16th Annual - Course Coordinator and Lecturer
New Orleans, LA (July 28-August 2, 1994)
Topics: "Overview of Clinical Pharmacology"
"Principles of Clinical Toxicology"

INVITED LECTURES AND SYMPOSIA: (cont'd)

Clinical Pharmacology for the Practicing Physician
Program Director and Lecturer
New Orleans, LA (April 22, 1995)

Topic: "Variability in Drug Metabolism and Adverse Drug
Reactions: Concepts and Practical Applications"

New Orleans Internal Medicine Board Review Course
17th Annual - Course Coordinator and Lecturer
New Orleans, LA (July 25-30, 1995)

Topic: "Overview of Clinical Pharmacology"

XI International Conference on AIDS
Vancouver, B.C., Canada (July 7-12, 1996)

Postgraduate Course in Clinical Pharmacology
Pan American Health Organization
Buenos Aires, Argentina (August 4, 1996)

Topic: "Variation in Drug Response and Polymorphic Drug Oxidation"

VI World Conference on Clinical Pharmacology Symposium
on "Anti-HIV Drugs: Clinical Pharmacology Perspective"
Buenos Aires, Argentina (August 6, 1996)

Topic: "Pharmacokinetics of Antiretroviral Drugs"

International AIDS Society - USA Symposium on "Improving the
Management of HIV Disease"
New Orleans, LA (April 5, 1997)

Lecture: "Antiretroviral Therapy: Pharmacokinetics and Drug Interactions"

Invited Speaker, Argentine Association of Experimental Pharmacology, XXXI Scientific
Meeting

Buenos Aires, Argentina (November 17-20, 1999)

Topic: Current Trends in Antiretroviral Therapy for HIV and AIDS

Attendee, Forum for Collaborative HIV Research
Noordwijk, The Netherlands (April 2000)

Topic: Drug Interaction Research in HIV Disease

9th Annual Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected
Issues in HIV Disease Management
Washington, DC (May 8, 2001)

Topic: Pharmacologic Aspects of HIV Therapy

INVITED LECTURES AND SYMPOSIA: (cont'd)

Johns Hopkins University
Division of Clinical Pharmacology
Baltimore, Maryland (November 8, 2006)
Seminar: “Clinical Pharmacology, Hurricanes and Tidal Waves: A Journey from
New Orleans to Bethesda and the NIH”

American Society for Clinical Pharmacology and Therapeutics
2007 Annual Meeting
Symposium on Education in Clinical Pharmacology
Anaheim, California (March 22, 2007)
Topic: “Clinical Pharmacology Education and Training at the NIH”

National Institutes of Health
NIH Clinical Center Grand Rounds
Bethesda, Maryland (May 23, 2007)
Topic: “Variability in Drug Response: Genetics, Kinetics, and Dynamics”

Thomas Jefferson University
Department of Pharmacology
Division of Clinical Pharmacology
Philadelphia, Pennsylvania (November 13, 2007)
Seminar: “Education and Training in Clinical Pharmacology: Role of the NIH, the
FDA, Private Foundations, and the Pharmaceutical Industry”

American Society for Clinical Pharmacology and Therapeutics
2008 Annual Meeting
Symposium on Drug Resistant Bacteria (Co-Chair)
Orlando, Florida (April 3, 2008)
“Magnitude of the Problem and Current Drug Development Strategies and
Guidelines used by Pharmaceutical Industry and the Food and Drug Administration”

University of California Washington Center
American Course on Drug Development and Regulatory Sciences
Washington, DC (February 1, 2010)
“Introduction to Pharmacokinetics, Drug Metabolism, and ADME Principles”

American Society for Clinical Pharmacology and Therapeutics
2010 Annual Meeting
Workshop on Educating Practitioners about Clinical Pharmacology
Atlanta, Georgia (March 19, 2010)
“Creating a Large Group Course and Using Distributive Educational Techniques”

NIH Research Festival – 2011
Translational Research Interest Group Symposium
Symposium on “Informing Therapeutic Interventions with Mechanism-Based Pharmacology
and Toxicology” (Co-Chair)
Bethesda, Maryland (October 24, 2011)

American Society for Clinical Pharmacology and Therapeutics
2012 Annual Meeting
Symposium on Progressive Multifocal Leukoencephalopathy (PML) (Co-Chair)
National Harbor, Maryland (March 15, 2012)
“Immunomodulatory Therapies and PML: Novel Approaches to Risk Minimization
and Treatment of JC Virus Infection”

Association of Clinical Pharmacology Units
2012 Annual Meeting
Symposium on “Drug Rescue and Repurposing Initiatives at the NIH” (Chair)
NIH Clinical Center – Bethesda, Maryland (April 26, 2012)

NIH Clinical Center – FDA CDER Joint Task Force
Training Course on IND Regulations and IND Submissions (Course Co-Chair)
“Investigational New Drug Applications: What you need to know for successful
Interactions with the FDA”
NIH Clinical Center – Bethesda, Maryland (December 12, 2013)

American Association of Colleges of Pharmacy (AACP)
Retreats for AACP Academic Research Fellows
“Education and Training Opportunities in Clinical Pharmacology and Clinical
Research at the NIH Clinical Center”
US Pharmacopeia, Rockville, Maryland (March 11, 2014)
Natcher Conference Center, NIH Campus, Bethesda, Maryland (September 10, 2014)

NIH Clinical Center – FDA CDER Joint Task Force
Training Course on IND Regulations and IND-Enabling Elements (Course Co-Chair)
“IND-Enabling Non-Clinical Safety Assessment of Candidate Drugs and
Good Laboratory Practice Standards”
NIH Clinical Center – Bethesda, Maryland (September 29, 2014)

NIH Clinical Center – Pharmacy Department – Pharmacotherapy Frontiers 2015
“Effects of Liver Disease on Drug Metabolism and Pharmacokinetics”
NIH Clinical Center – Bethesda, Maryland (April 25, 2015)

EDITORIAL BOARD MEMBERSHIP:

Clinical Pharmacology and Therapeutics 1986-2016

EDITORIAL REVIEWS:

American Journal of Diseases in Children
Annals of Internal Medicine
Blood
British Journal of Clinical Pharmacology
Clinical Infectious Diseases
Clinical Pharmacokinetics
Clinical Pharmacology & Therapeutics
Critical Care Medicine
Hypertension
Journal of Cardiovascular Pharmacology
Journal of Clinical Pharmacology
Journal of Laboratory and Clinical Medicine
Nephron
Pharmacological Reviews
Proceedings of the Society for Experimental Biology and Medicine
Steroids

ADMINISTRATIVE SERVICE:

Northwestern University Medical School Clinical Pharmacology Center Assistant Training Program Director	1979-80
Tulane University School of Medicine Departments of Medicine and Pharmacology Head, Section of Clinical Pharmacology	1981-2006

ADMINISTRATIVE SERVICE: (con't)

Tulane University School of Medicine
Department of Pharmacology
Associate Director, Tulane Drug Analysis Laboratory 1981-2006

Tulane-Charity-LSU
General Clinical Research Center (NIH-NCRR)
Program Director 1998-2005

COMMITTEE SERVICE:

National Committees:

Member, Constitution and By-Laws Committee, American
Society for Clinical Pharmacology and Therapeutics 1984-1989

Member, Membership Committee
American Society for Clinical Pharmacology and Therapeutics 1987-1989

Member, Scientific Program Committee for the 89th
Annual Meeting (1988)
American Society for Clinical Pharmacology and Therapeutics 1987-1988

Member, Medical Education Committee
American Society for Clinical Pharmacology and Therapeutics 1989-1992

Chairperson, Cardiovascular and Pulmonary Section
American Society for Clinical Pharmacology and Therapeutics 1988-1992

Member, Board of Directors
American Society for Clinical Pharmacology and Therapeutics 1994-1997
2007-2011

Vice-Chairperson, Scientific Program Committee for the
96th Annual Meeting (1995)
American Society for Clinical Pharmacology and Therapeutics 1994-1995

Vice-Chairperson, Committee on Coordination of Scientific Sections
American Society for Clinical Pharmacology and Therapeutics 1995-1996

Chairperson, Scientific Program Committee for the
97th Annual Meeting (1996)
American Society for Clinical Pharmacology and Therapeutics 1995-1996

Chairperson, Committee on Coordination of Scientific Sessions
American Society for Clinical Pharmacology and Therapeutics 1996-1998

Member, ACTG Pharmacology Committee 1987-1993

National Committees: (cont'd)

AIDS Clinical Trials Group (NIAID)	1999-2001 2002-2005
Member, Pediatric Pharmacology Working Group, AIDS Clinical Trials Group (NIAID)	1993-1995
Member, NIH Site Visit Team, National Center for Research Resources (University of Alabama at Birmingham GCRC) April 23-24, 1992	1992
Member, Executive Committee American Board of Clinical Pharmacology	1996-99
Member, ABMS Specialty Board Committee American Board of Clinical Pharmacology	1994-2000
Member, Accreditation of Programs Committee American Board of Clinical Pharmacology	1994-2000
Member, Scientific Committee, Third International Workshop On the Clinical Pharmacology of Anti-HIV Drugs Washington, DC, April 20	2002
Member, AIDS Clinical Studies and Epidemiology Study Section National Institutes of Health	2001-2005
Member, Advisory Committee, Clinical Pharmacology Fellowship Training Program, Johns Hopkins University	2006-present
Member, Curriculum Committee, American Course on Drug Development and Regulatory Sciences. University of California – San Francisco	2006-2008
Member, US Pharmacopeial Convention (NIH representative)	2007-2010
Member, NIAID Intramural Scientific Review Committee	2007-2016
Member, FDA Advisory Committee on Pharmaceutical Science and Clinical Pharmacology	2008-2011

University Committees:

Northwestern University Institutional Review Board (Member)	1978-79
Institutional Review Board (Panel Chairman)	1979-80
Northwestern University Faculty Senate (Member)	1978-79

Medical School Committees:

Tulane University School of Medicine

Medical School Committees: (con't)

Clinical Pharmacology Steering Committee (Chairman)	1981-82
Clinical Pharmacology Advisory Committee (Chairman)	1982-83
Faculty Advisory Committee (Basic Science Representative)	1982-85
Biomedical Research Support Grant Review Committee (Member)	1985
Selection Committee for the J.U. Schlegel Award for Excellence in Research (Member)	1988
Committee on Use of Human Subjects (IRB) (Vice-Chairman)	1981-94
(Chairman)	1994-96
Personnel and Honors Committee (Member)	1989-92
International Projects Coordinating Committee (Member)	1989-91
General Clinical Research Center Advisory Committee (Chairman)	1990-98
Faculty Committee on Clinical Research (Chairman)	1990-92
Housestaff Appeals Board (Member)	1993-94

Departmental Committees:

Department of Pharmacology-Tulane School of Medicine Medical Pharmacology Course Committee	1981-1996
Pharmacology for Nurse Practitioners Course Director, Tulane-Loyola	1996-2000
Department of Medicine-Tulane School of Medicine Finance Committee	1985-86
Intern Interview Committee	1991-1993
Member, Infectious Diseases Task Force	1995-2000

Hospital Committees:

Northwestern Memorial Hospital Committee on Pharmacy and Therapeutic Drugs (Member)	1977-80
--	---------

Hospital Committees: (con't)

Tulane Medical Center Hospital	
Pharmacy and Therapeutics Committee (Member)	1981-82
Antibiotics Review Subcommittee (Member)	1991-92
Investigational Studies Subcommittee (Chairman)	1985-93
Pharmacy and Therapeutics Committee (Chairman)	1982-2005
International Relations Committee (Chairman)	1987
Quality Care Committee (Member)	1988-2005
Medical Center of Louisiana-New Orleans (Charity Hospital)	
Tulane-LSU-Charity Hospital GCRC	
GCRC Advisory Committee (Chairman)	1991-2006
Veterans Administration Hospital	
Therapeutic Agents and Pharmacy Review Committee (Member)	1986-2005
(Chairman)	1994-2001
Drug Usage Evaluation Committee (Member)	1993-96
NIH Clinical Center	
Clinical Pharmacology Steering Committee (Chairman)	2006-2016
Pharmacy and Therapeutics Committee (Member)	2006-2016
Search Committee, Pharmacy Dept. Director (Member)	2007/2015
Pharmacogenetics Testing Subcommittee (Co-Chair)	2010-2016
Pharmacogenetics Implementation Committee (Chairman)	2010-2013
NIH Clinical Center-FDA CDER Joint Task Force (Co-Chair)	2012-2016

PATENTS

"Use of Desethyl-N-Acetylprocainamide (NAPADE) as an Inotropic Agent" (U.S. Patent No. 4,555,525). Juan J. L. Lertora, M.D., Ph.D., Lucy W. King, B.S., and The Administrators of the Tulane Educational Fund. (November 26, 1985)	1985
--	------

PUBLICATIONS:

Books and Book Chapters

Cheng S, Vanevski KM, Lertora JLL. Clinical Pharmacology and its Role in Pharmaceutical Development. In: *Principles and Practice of Clinical Research* (4th Edition), Gallin JI, Ognibene FP, Johnson LL (Editors), pp 645-659, Academic Press, London, UK; Waltham; San Diego, 2017

Atkinson AJ, Jr., Huang S-M, Lertora JLL, Markey SP (Editors), *Principles of Clinical Pharmacology* (3rd Edition), Academic Press, London, UK; Waltham; San Diego, 2012

Atkinson AJ, Jr., Lertora JLL. Effect of Renal Disease on Pharmacokinetics. In: *Principles of Clinical Pharmacology* (3rd Edition), Atkinson AJ, Jr., *et al* (Editors), pp 55-64, Academic Press, London, UK; Waltham; San Diego, 2012

Susla GM, Lertora, JLL. Effect of Liver Disease on Pharmacokinetics. In: *Principles of Clinical Pharmacology*, (3rd Edition), Atkinson AJ, Jr., *et al* (Editors), pp 81-96, Academic Press, London, UK; Waltham; San Diego, 2012

Lowe ES, Lertora, JLL. Dose-Effect and Concentration-Effect Analysis. In: *Principles of Clinical Pharmacology* (3rd Edition), Atkinson AJ, Jr., *et al* (Editors), pp 343-356, Academic Press, London, UK; Waltham; San Diego, 2012

Lertora JLL, Vanevski KM. Clinical Pharmacology and its Role in Pharmaceutical Development. In: *Principles and Practice of Clinical Research* (3rd Edition), Gallin JI, Ognibene FP (Editors), pp 627-639, Academic Press, London, UK; Waltham; San Diego, 2012

Lertora JLL, Vanevski KM. Introduction to Pharmacokinetics and Pharmacodynamics. In: *Small Molecule Therapy for Genetic Disease*, Thoene, JG (Editor), pp 35-54, Cambridge University Press, Cambridge, UK; New York, 2010

Berggren RE, Clay PG, Lertora JLL. Ribavirin. In: *Antimicrobial Therapy and Vaccines. Volume II: Antimicrobial Agents* (2nd Edition). Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD (Editors), pp 909-922, ESun Technologies, Pittsburgh, 2005

Lertora JLL, Foster ME. Adverse drug reactions and interactions of antiretroviral drugs. In: *AIDS and Associated Diseases* (3rd Edition), Benetucci J (Editor), pp 733-762, FUNDAI, Buenos Aires, 2008

Lertora JLL, Strada RA. Toxic effects and pharmacologic interactions of antiretrovirals. In: *AIDS and Associated Diseases* (2nd Edition), Benetucci J (Editor), pp 671-697, FUNDAI, Buenos Aires, 2001

Lertora JLL, Mark AL, Johannsen J, Wilson WR, Abboud FM. Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon. In: *The Year Book of Anesthesia*. Eckenhoff JE (ed), pp 64-65, Year Book Medical Publishers, Chicago, 1976

Fisher JW, Moriyama Y, Lertora JLL, Rege AB, Dukes PP. Mechanisms of the anemia of renal disease. In: *Erythropoiesis*. Nakao K, Fisher JW, Takaku F (Eds), pp 463-480, Baltimore: University Park Press, 1975

Fisher JW, Espada J, Taylor P, Lertora JLL, Roh BL. A radioimmunoassay for human urinary erythropoietin. In: *Regulation of Erythropoiesis*. Gordon AS, Condorelli M, Peschle C. (Editors), pp 122-131, The Publishing House "Il Ponte", Milano, Italy, 1972

Manuscripts

1. Fisher JW, **Lertora JLL**, Lindholm DD, Tornoyos K, Moriyama Y. Erythropoietin production and inhibitors in serum in the anemia of uremia. *Proc Clin Dial Transplant Forum* 3:22-32, 1973
2. Lindholm DD, Fisher JW, Vieira JA, Dombeck DH, Bernal G, **Lertora JLL**. Clinical effects of oral fluoxymesterone in patients with dialysis-controlled uremia. *Trans Am Soc Artif Intern Organs* 19:475-483, 1973
3. Moriyama Y, **Lertora JLL**, Fisher JW. Studies on an inhibitor of erythropoiesis. I. Effects of sera from normal and polycythemic rabbits on heme synthesis in rabbit bone marrow cultures. *Proc Soc Exp Biol Med* 147:740-743, 1974
4. **Lertora JLL**. The role of erythropoietin in the anemia of renal disease. Doctoral Dissertation (PhD), Tulane University, New Orleans, Louisiana. *Dissertation Abstracts International* 35: 1830B-1831B, 1974
5. Fisher JW, Moriyama Y, Rege AB, Tornoyos K, **Lertora JLL**. The role of inhibitors of heme synthesis and bone marrow erythroid colony forming cells in the mechanism of anemia of renal insufficiency. *Proc Clin Dial Transplant Forum* 4:141-146, 1974
6. Fisher JW, Moriyama Y, **Lertora JLL**, Rege AB, Dukes PP. Mechanisms of the anemia of renal disease. In: *Erythropoiesis*. Nakao K, Fisher JW, Takaku F (Eds), pp 463-480, Baltimore: University Park Press, 1975
7. **Lertora JLL**, Dargon PA, Rege AB, Fisher JW. Studies on a radioimmunoassay for human erythropoietin. *J Lab Clin Med* 86:140-151, 1975
8. **Lertora JLL**, Gomez-Perez FJ, Leslie GA. Structure and biological function of human IgD. V. Insulin antibodies of the IgD class in sera from some diabetic patients. *Int Arch Allergy Appl Immunol* 49:597-606, 1975
9. **Lertora JLL**, Mark AL, Johannsen J, Wilson WR, Abboud FM. Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon. *J Clin Invest* 56:719-724, 1975
10. Fisher JW, Moriyama Y, **Lertora JLL**. Mechanisms of androgen stimulated erythropoiesis

- and inhibitors of heme synthesis in uremia. *Blood Cells* 1:573-597, 1975
11. Fisher JW, Foley JE, Moriyama Y, Ohno Y, Modder B, **Lertora JLL**. Studies on the mechanism of the anemia of renal insufficiency. *Proc Clin Dial Transplant Forum* 6:42-49, 1976
 12. **Lertora JLL**, Mark AL, Johannsen J, Wilson WR, Abboud FM. Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon. In: *The Year Book of Anesthesia*. Eckenhoff JE (ed), pp 64-65, Chicago: Year Book Medical Publishers, Inc, Chicago, 1976
 13. Burk JR, **Lertora JLL**, Martinez IR Jr, Fisher JW. Renal cell carcinoma with erythrocytosis and elevated erythropoietic stimulatory activity. *South Med J* 70:955-158, 1977
 14. **Lertora JLL**, Atkinson AJ Jr, Kushner W, Nevin MJ, Lee WK, Jones C, Schmid FR. Long-term antiarrhythmic therapy with N-acetylprocainamide. *Clin Pharmacol Ther* 25:273-282, 1979
 15. Stec GP, **Lertora JLL**, Atkinson AJ Jr, Nevin MJ, Kushner W, Jones C, Schmid FR, Askenazi J. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. *Ann Intern Med* 90:799-801, 1979
 16. **Lertora JLL**, Glock D, Stec GP, Atkinson AJ Jr, Goldberg LI. Effects of N-acetylprocainamide and procainamide on myocardial contractile force, heart rate, and blood pressure. *Proc Soc Exp Biol Med* 161:332-336, 1979
 17. Atkinson AJ Jr, Stec GP, **Lertora JLL**, Ruo TI, Thenot J-P. Impact of active metabolites on monitoring plasma concentrations of therapeutic drugs. *Ther Drug Monit* 2:19-27, 1980
 18. **Lertora JLL**, Stec GP, Kushner W, Eudeikis JR. The hemodynamic actions of N-acetylprocainamide in dogs: Kinetics of effects and plasma concentration-response relationships. *Proc Soc Exp Biol Med* 164:128-136, 1980
 19. Stec GP, Ruo TI, Thenot J-P, Atkinson AJ Jr, Morita Y, **Lertora JLL**. Kinetics of N-acetylprocainamide deacetylation. *Clin Pharmacol Ther* 28:659-666, 1980
 20. Eudeikis JR, Henthorn TK, **Lertora JLL**, Atkinson AJ Jr, Chao GC, Kushner W. Kinetic analysis of the vasodilator and ganglionic blocking actions of N-acetylprocainamide. *J Cardiovasc Pharmacol* 4:303-309, 1982
 21. Maloney JM III, **Lertora JLL**, Yarborough J, Millikan LE. Plasma concentrations of lidocaine during hair transplantation. *J Dermatol Surg Oncol* 8:950-954, 1982 (Erratum in p 1034)
 22. Atkinson AJ Jr, **Lertora JLL**, Kushner W, Chao GC, Nevin MJ. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. *Clin Pharmacol Ther* 33:565-576, 1983
 23. Rege AB, **Lertora JLL**, White LE, George WJ. Rapid analysis of valproic acid by gas chromatography. *J Chromatogr* 309:397-402, 1984

24. Woo FL, Johnson AP, Caldwell DR, **Lertora JLL**, George WJ. Piperacillin levels in human tears and aqueous humor. *Am J Ophthalmol* 98:17-20, 1984
25. **Lertora JLL**, King LW. Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. *J Pharmacol Exp Ther* 238:893-899, 1986
26. **Lertora JLL**, King LW, Donkor KA. The inotropic actions of N-acetylprocainamide: blockade and reversal by propranolol. *Angiology* 37:939-949, 1986
27. McCloskey SE, Gershanik JJ, **Lertora JLL**, White L, George WJ. Toxicity of benzyl alcohol in adult and neonatal mice. *J Pharm Sci* 75:702-705, 1986
28. Fu JS, **Lertora JLL**, Brookins J, Rice JC, Fisher JW. Pharmacokinetics of erythropoietin in intact and anephric dogs. *J Lab Clin Med* 111:669-676, 1988
29. Ricci MJ, Benoit CA, **Lertora JLL**, George WJ. Melanin and other indole compounds do not cause false-positive cannabinoid assay results. *Clin Chem* 35:1809, 1989
30. Gogu SR, **Lertora JLL**, George WJ, Hyslop NE, Agrawal KC. Protection of zidovudine-induced toxicity against murine erythroid progenitor cells by vitamin E. *Exp Hematol* 19:649-652, 1991
31. **Lertora JLL**, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, Hyslop NE Jr. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. *Clin Pharmacol Ther* 50:442-449, 1991
32. Rege AB, Walker-Cador JY, Clark RA, **Lertora JLL**, Hyslop NE Jr, George WJ. Rapid and sensitive assay for fluconazole which uses gas chromatography with electron capture detection. *Antimicrob Agents Chemother* 36:647-650, 1992
33. Lupia RH, Ferencz N, **Lertora JLL**, Aggarwal SK, George WJ, Agrawal KC. Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. *Antimicrob Agents Chemother* 37:818-824, 1993
34. **Lertora JLL**, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE Jr, Agrawal KC. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. *Clin Pharmacol Ther* 56:272-278, 1994
35. Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, **Lertora JLL**. Urinary excretion of 6-OH-chlorzoxazone as an index of cytochrome P2E1 activity. *Clin Pharmacol Ther* 58:498-505, 1995
36. Japour AJ, **Lertora JJ**, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth DK, Bassiakos Y, Crumpacker CS for the AIDS Clinical Trials Group 231 protocol team. A phase I study of the safety, pharmacokinetics and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. *J Acquir Immune Defic*

- Syndr Hum Retrovirol 13:235-246, 1996
37. Akula SK, Rege AB, Dreisbach AW, Depace PJMT, **Lertora JLL**. Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. *Am J Med Sci* 313(4):244-246, 1997
 38. **Lertora JJ**. Current trends in antiretroviral therapy for HIV infection and AIDS. *Medicina (Buenos Aires)* 59:533-534, 1999
 39. Kusus M, Stapleton DD, **Lertora JLL**, Simon EE, Dreisbach AW. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. *Am J Med Sci* 1:394-397, 2000
 40. **Lertora JLL**, Strada RA. Toxic effects and pharmacologic interactions of antiretrovirals. In: *AIDS and Associated Diseases*, 2nd Ed., Chapter 37, pp 671-697, Buenos Aires: FUNDAI, 2001
 41. Ellis K, Dreisbach AW, **Lertora JLL**. Plasma elimination of cardiac troponin I in end-stage renal disease. *So Med J* 94:993-996, 2001
 42. Rozans M, Dreisbach A, **Lertora JLL**, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. *J Clin Oncol* 20:335-339, 2002
 43. Dreisbach AW, **Lertora JJ**. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. *Semin Dial* 16:45-50, 2003
 44. Dreisbach AW, Japa S, Gebrekal AB, Mowrey SE, **Lertora JLL**, Kamath BL, Rettie AE. Cytochrome P4502C9 in end-stage renal disease. (Letter) *Clin Pharmacol Ther* 75(3):475-477, 2003
 45. Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanj SL, Rettie AE, Kim H, Farin FM, **Lertora JLL**. The prevalence of CYP2C8, 2C9, 2J2 and soluble epoxide hydrolase polymorphisms in African-Americans with hypertension. *Am J Hypertens* 18: 1276-1281, 2005
 46. Cohn SE, Park J-G, Watts DH, Stek A, Hitti J, Clax PA, Yu S, **Lertora JLL**, for the ACTG A5093 Protocol Team. Depo-medroxyprogesterone in women on antiretroviral therapy: Effective contraception and lack of clinically significant interactions. *Clin Pharmacol Ther* 81:222-227, 2007
 47. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy P, Kilby JM, Lederman MM, Hamilton CD, **Lertora J**, White BL, Tebas P, Duliege AM, Pollard RB; for the AIDS Clinical Trials Group 328 Study Team. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection. *Arch Intern Med* 167:597-605, 2007
 48. Mzayek F, Haiyan D, Mather FJ, Wasilevich EC, Liu H, Hadi CM, Chansolme DH, Murphy HA, Melek BH, Tenaglia AN, Mushatt DM, Dreisbach AW, **Lertora JLL**, Krogstad DJ. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and

- chloroquine in healthy volunteers.
PLoS Clin Trials 2(1):e6.doi:10.1371/journal.pctr.0020006, 2007
49. Li M, Maderdrut JL, **Lertora JJ**, Batuman V. Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. *Peptides* 28:1891-1895, 2007
 50. **Lertora JLL**, Atkinson AJ. Clinical pharmacology education and training at the National Institutes of Health. *Clin Pharmacol Ther* 81:907-909, 2007
 51. Li M, Maderdrut JL, **Lertora JJ**, Arimura A, Batuman V. Renoprotection by pituitary Adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. *Regul Pept* 145:24-32, 2008
 52. Watts DH, Park J-G, Cohn SE, Yu S, Hitti J, Stek A, Clax PA, Muderspach L, **Lertora JLL**. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. *Contraception* 77:84-90, 2008
 53. Dreisbach AW, Rice JC, Japa S, Newman JW, Sigel A, Gill RS, Hess AE, Cemo AC, Fonseca JP, Hammock BD, **Lertora JJ**, Hamm LL. Salt loading increases urinary excretion of linoleic acid diols and triols in healthy human subjects. *Hypertension* 51:755-761, 2008
 54. Dreisbach AW, **Lertora JJ**. The effect of chronic renal failure on drug metabolism and transport. *Expert Opin Drug Metab Toxicol* 4:1065-1074, 2008
 55. Di Mascio M, Srinivasula S, Bhattacharjee A, Cheng L, Martiniova L, Herscovitch P, **Lertora J**, Kiesewetter D. Antiretroviral tissue kinetics: *in vivo* imaging using positron emission tomography. *Antimicrob Agents Chemother.* 53:4086-4095, 2009
 56. Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, **Lertora J**, Patterson KB, Daar ES, Cavert W. Brizz B; ACTG A5200 Team of the ACTG. Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200. *J Acquir Immune Defic Syndr* 53:491-495, 2010
 57. Asmuth DM, Murphy RL, Rosenkranz SL, **Lertora JJ**, Kottlil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li X-D, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB. Safety, tolerability and mechanisms of antiretroviral activity of peginterferon alfa-2a in HIV-1-mono-infected subjects: A phase II clinical trial. *J Infect Dis* 201:1686-1696, 2010
 58. Bausch DG, Hadi CM, Khan SH, **Lertora JLL**. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. *Clin Infect Dis* 51:1435-1441, 2010
 59. Khan E, Batuman V, **Lertora JLL**. Emergence of biomarkers in nephro pharmacology. *Biomarkers Med.* 4:805-814, 2010

60. Goldspiel BR, Flegel WA, Dipatrizio G, Sissung T, Adams SD, Penzak SR, Biesecker LG, Fleisher TA, Patel JJ, Herion D, Figg WD, **Lertora JJ**, McKeeby JW. Integrating pharmacogenetic information and clinical decision support into the electronic health record. *J Am Med Inform Assoc* 21:522-528, 2014
61. Sissung TM, McKeeby JW, Patel J, **Lertora JJ**, Kumar P, Flegel WA, Adams SD, Eckes EJ, Mickey F, Plona TM, Mellott SD, Baugher RN, Wu X, Soppet DR, Barcus ME, Datta V, Pike KM, DiPatrizio G, Figg WD, Goldspiel BR. Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. *J Clin Pharmacol* 57(S10):S67-S77, 2017
62. Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, La Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung W-H, Dalton AD, Hung S-I, Lee MTM, Leeder JS, **Lertora JLL**, Mahasirimongkol S, McLeod HL, Mockenhaupt M, Pacanowski M, Phillips EJ, Pinheiro S, Pirmohamed M, Sung C, Suwankesawong W, Trepanier L, Tumminia SJ, Veenstra D, Yuliwulandari R, Shear NH. Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. *Clin Pharmacol Ther* 2017 Nov 6. Doi:10.1002/cpt.890.[Epub ahead of print]
63. Remy KE, Cortes-Puch I, Solomon SB, Sun J, Pockros BJ, Feng J, **Lertora JJ**, Hangtan, RR, Liu X, Perlegas A, Shaw Warren H, Gladwin MT, Kim-Shapiro DB, Klein HG, Natanson C. *JCI Insight* 2018 Sep 20; 3(18):e123013.
64. Rebello CJ, Beyl RA, **Lertora JLL**, Greenway FL, Ravussin E, Ribnicky DM, Poulev A, Kennedy BJ, Castro HF, Campagna SR, Coulter AA, Redman LM. Safety and pharmacokinetics of naringenin: A randomized, controlled, single ascending dose, clinical trial. *Diabetes Obes Metab*. 2019 Aug 29; doi: 10.1111/dom. 13868. [Epub ahead of print]

ABSTRACTS:

1. Lertora JLL, Noveck R, Fisher JW. Inhibitory effects of renal extracts on erythroid cells and heme in bone marrow cultures. *Fed Proc* 30:683, 1971
2. Stuckey WJ, Fisher JW, Lindholm D, Beltran G, Lertora JLL. The study of anemia in patients with renal disease. 5th Annual Contractors Conference, Artificial Kidney-Chronic Uremia Program (NIAMD), Bethesda, MD, pp 143a-143b, Jan 24-26, 1972
3. Lertora JLL, Roh BL, Fisher JW. Effects of erythropoietin on normal and anephric rabbit bone marrow cultures. 15th Meeting of the American Society of Hematology, 1972
4. Roh BL, Samuels AI, Lertora JLL, Paulo LG, Fisher JW. Erythropoietic effects of androgens in exhypoxic polycythemic mice and in rabbit bone marrow cells *in vitro*. 15th Meeting of the American Society of Hematology, p 105, 1972
5. Lertora JLL, Dargon PA, Fisher JW. Radioimmunoassay of erythropoietin in serum from normal and anemic uremic human subjects. *Fed Proc* 32:872, 1973
6. Lertora JLL, Moriyama Y, Tornoyos K, Lindholm K, Fisher JW. Inhibitory effects of serum from

- anemic uremic patients on heme synthesis in bone marrow cultures from normal and anemic uremic subjects. 6th Annual Meeting American Society of Nephrology, Washington, DC, p 65, Nov, 1973
7. Moriyama Y, Lertora J.J.L., Fisher J.W. Response of uremic rabbit bone marrow cultures *in vitro* to erythropoietin and testosterone. 6th Annual Meeting American Society of Nephrology, Washington, DC, p 76, Nov, 1973
 8. Moriyama Y, Lertora J.J.L., Fisher J.W. Inhibitory effects of normal, uremic and polycythemic rabbit sera on heme synthesis in rabbit bone marrow cultures. 16th Meeting of the American Society of Hematology, p 160, 1973
 9. Moriyama Y, Lertora J.J.L., Rege A, Fisher J.W. Inhibitors of erythropoiesis in uremia. Fed Proc 33:597, 1974

ABSTRACTS: (con't)

10. Moriyama Y, Lertora JLL, Fisher JW. Response of uremic rabbit bone marrow cultures *in vitro* to erythropoietin and testosterone. Clin Res 22:67A, 1974
11. Rege AB, Lertora JLL, Fisher JW. Iodination methods for the radioimmunoassay of erythropoietin. 17th Annual Meeting American Society of Hematology, Atlanta, GA, p 78, 1974
12. Lertora JLL, Mark AL, Johannsen UJ, Wilson WR, Abboud FM. Selective beta-1 receptor blockade with oral practolol in man. Clin Res 22:598A, 1974
13. Lertora JLL, Atkinson AJ Jr, Kushner W, Nevin MJ, Lee WK, Jones C, Schmid FR. Long-term antiarrhythmic therapy with N-acetylprocainamide. Clin Res 26:487A, 1978
14. Lertora JLL, Glock D, Stec GP, Atkinson AJ Jr, Goldberg LI. Effects of N-acetylprocainamide and procainamide on myocardial contractile force. Fed Proc 38:696, 1979
15. Stec GP, Ruo TI, Thenot J-P, Atkinson AJ Jr, Morita Y, Lertora JLL. Kinetics of N-acetylprocainamide deacetylation in man. Clin Res 28:760A, 1980
16. Eudeikis JR, Henthorn TK, Lertora JLL, Atkinson AJ Jr, Chao GC, Kushner W. Kinetic analysis of the vasodilator and ganglionic blocking actions of N-acetylprocainamide. Clin Res 29:755A, 1981
17. Gershanik JJ, Boecler B, Lertora JLL, Sola A, Leitner M, Kapadia C. Monitoring levels of trichloroethanol during chloral hydrate administration to sick neonates. Clin Res 29:895A, 1981
18. Lertora JLL, King LW, Donkor KA. The inotropic actions of N-acetylprocainamide: blockade and reversal by propranolol. Clin Res 31:834A, 1983
19. McCloskey SE, Lertora JLL, Gershanik JJ, George WJ. The effect of disulfiram on benzyl alcohol toxicity. Clin Res 31:852A, 1983
20. Woo FL, Johnson AP, Caldwell DR, Lertora JLL, George WJ. Piperacillin (PIP) levels in human aqueous humor. Pharmacologist 25:150, 1983
21. Lertora JLL, Underwood DC, King LW, Rege AB. Cardiovascular actions of desethyl-N-acetylprocainamide (NAPADE). Clin Pharmacol Ther 35:255, 1984
22. Lertora JLL, King LW. The pharmacokinetics of desethyl-N-acetylprocainamide (NAPADE) in the dog. Clin Res 32:835A, 1984
23. Smith WB, Lertora JLL, Phillips JH. Amiodarone therapy for refractory atrial and ventricular arrhythmias. Clin Res 32:833A, 1984
24. Fu JS, Lertora JLL, Brookins J, Fisher JW. The pharmacokinetics of erythropoietin in the dog. Pharmacologist 27:202, 1985

ABSTRACTS: (con't)

25. Lertora JLL, Smith WB, George WJ, Rege AB, Solomito JA, Pinsky WW, Weinstein EW, Wang T, Phillips JH. Monitoring amiodarone and reverse T₃ levels in patients with refractory arrhythmias. Clin Res 34:178A, 1986
26. Michael RC, Lertora JLL, Clarkson CW, Wang T, King LW. Inotropic actions of procainamide and desethyl-N-acetylprocainamide (NAPADE) in cat papillary muscle. Clin Res 34:178A, 1986
27. McCloskey SE, Lertora JLL, Gershanik JJ, White LA, Simoneaux D, George WJ. Toxicity of benzyl alcohol in adult and neonatal mice. Clin Res 34:197A, 1986
28. Fu JS, Lertora JLL, Brookins J, Fisher JW. The pharmacokinetics of recombinant erythropoietin in intact and anephric dogs. Pharmacologist 28:203, 1986
29. Francovitch RJ, Schor NA, Lertora JJ, George WJ. Effects of SKF 525-A and phenobarbital on ethylene dichloride toxicity. J Am Coll Toxicol 5:117, 1986
30. Wang T, King LW, Phillips JH, Lertora JLL. Test of NAPADE in a conscious dog model of ventricular arrhythmias. Clin Res 35:10A, 1987
31. Lertora JLL, Michael RC, Clarkson CW, Wang T, King LW. Inotropic and arrhythmogenic actions of procainamide, N-acetylprocainamide and desethyl-N-acetylprocainamide in cat papillary muscle. Clin Pharmacol Ther 41:234, 1987
32. McCloskey SE, Rege AB, Lertora JLL, George WJ, Agrawal KC, Hyslop NE. Zidovudine pharmacokinetics and plasma levels in patients with HIV infection. Clin Res 36:21A, 1988
33. McCloskey SE, Rege AB, Lertora JLL, George WJ, Agrawal KC, Hyslop NE. Monitoring AZT plasma levels in patients with HIV-infection. Clin Pharmacol Ther 43:123, 1988
34. Rangan SRS, Rege A, Risi G, Lertora J, Valainis G, Hyslop N. Changes in HIV neutralizing antibody levels associated with AZT treatment in AIDS. Fourth International Conference on AIDS, Stockholm, Sweden, June 12-16, Abstract No. 3131:252, 1988
35. Agrawal KC, Aggarwal SK, Gogu SR, Lupia RH, Lertora JLL, Rangan SRS. Isoleucine ester of zidovudine as a pro-drug with enhanced efficacy against HIV-1. Fifth International Conference on AIDS, Montreal, Canada, June 4-9, Abstract No. M.C.P. 64:552, 1989
36. Lertora JJ, Rege AB, Ferencz N, Lacour JT, Ernst-Triana L, Jeffers T, George WJ, VanDyke RB, Agrawal KC, Hyslop NE. Pharmacokinetics of ribavirin in asymptomatic HIV-infected patients. Clin Res 38:7A, 1990
37. Ferencz N, Lupia RH, Lertora JJ. Changes in inulin and gallamine distribution clearance caused by phenylephrine and nitroprusside. Clin Res 38:6A, 1990
38. Lupia R, Ferencz N, Aggarwal S, Agrawal K, Lertora JJ. Plasma, cerebrospinal fluid and brain pharmacokinetics of two novel prodrugs of zidovudine. Clin Res 38:15A, 1990

ABSTRACTS: (con't)

39. Ferencz N, Lupia RH, Lertora JJ. Perturbation of inulin and gallamine pharmacokinetics by phenylephrine and nitroprusside. *Clin Pharmacol Ther* 47:181, 1990
40. Lupia R, Ferencz N, Aggarwal S, Agrawal K, Lertora JJ. Plasma, cerebrospinal fluid and brain pharmacokinetics of an isoleucine ester of zidovudine. *Clin Pharmacol Ther* 47:176, 1990
41. Lupia R, Ferencz N, Agrawal KC, Aggarwal S, Lertora JJ. Two novel prodrugs enhance levels of zidovudine in brain. *Clin Res* 38:952A, 1990
42. Ferencz N, Lupia RH, Lertora JJJ. Phenylephrine-induced perturbation of gallamine intercompartmental clearance and neuromuscular blockade under physiologic and constant blood flow conditions. *Clin Res* 38:968A, 1990
43. Lupia R, Ferencz N, Aggarwal S, Agrawal K, Lertora JJ. Enhanced levels of zidovudine in brain after treatment with two prodrugs. *Clin Pharmacol Ther* 49:198, 1991
44. Lertora JJJ, Rege AB, Lacour JT, Ferencz N, Morgan J, Williams D, Earnst-Triana L, George WJ, VanDyke RB, Agrawal KC, Hyslop NE Jr. Steady-state pharmacokinetics and long-term tolerance to ribavirin in HIV-infected patients. *Clin Res* 39:440A, 1991
45. Lertora JJJ, Akula S, Greenspan DL, Rege AB, Agrawal KC, George WJ, Hyslop NE. Valproic acid inhibits zidovudine glucuronidation in patients with HIV infection. VIII International Conference on AIDS, Amsterdam, The Netherlands, July 19-24, 3:100 (Pub. 7307), 1992
46. Lertora JJJ, Greenspan DL, Rege AB, Akula S, George WJ, Hyslop NE, Agrawal KC. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. *Clin Res* 40:781A, 1992
47. Lertora JJJ, Greenspan DL, Rege AB, Akula S, George WJ, Hyslop NE. Valproic acid inhibits glucuronidation of zidovudine (AZT) in HIV-infected patients. *Clin Pharmacol Ther* 53:197, 1993
48. Ferencz N, Lupia R, Lertora JJJ. Vasopressor-induced changes in neuromuscular blockade during physiologic and constant blood flow. *Clin Pharmacol Ther* 53:137, 1993
49. Alston B, Mitsuyosu R, Lertora J, Flexner C, Timpone J, van der Horst C. Phase I study of SCD4-PE40 in HIV infected persons. IX International Conference on AIDS, Berlin, Germany, June 6-11, 1993, Abstr No. PO-B29-2178:498, 1993
50. Akula SK, Rege AB, Dreisbach AW, George WJ, Dejace P, Lertora JJJ. Pharmacokinetic interactions between zidovudine and valproic acid in a patient with AIDS dementia. *J Invest Med* 43:16A, 1995

ABSTRACTS: (con't)

51. Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, Lertora JLL. Urinary excretion of 6-OH-chlorzoxazone is formation rate limited. *Clin Pharmacol Ther* 57: 217, 1995
52. Dreisbach AW, Ferencz N, Hopkins NE, Rege AB, George WJ, Lertora JLL. Hydroxylation index for chlorzoxazone as a measure of cytochrome P4502E1 activity. *Clin Res* 41:758A, 1993
53. Dreisbach AW, Ferencz N, Hopkins NE, Rege AB, George WJ, Lertora JLL. Urinary excretion of 6-OH-chlorzoxazone as an index of cytochrome P4502E1 activity. *Clin Pharmacol Ther* 55:250, 1994
54. Alvarado L, Fuentes MG, Brown K, Dreisbach AW, George WJ, Lertora JJ. Chlorzoxazone hydroxylation in male and female subjects as an index of CYD2E1 activity. *J Invest Med* 44: 60A, 1996
55. Alvarado L, Fuentes MG, Brown K, Dreisbach AW, George WJ, Lertora JJ. Role of ethnicity in chlorzoxazone hydroxylation and CYP2E1 activity. *Clin Pharmacol Ther* 59:137, 1996
56. Michel RE, Brown KM, Tally CM, Lertora JLL, George WJ. Ion pair high performance liquid chromatography method for the quantitation of DDI, DDC, 3TC, D4T and AZT from a single plasma sample. *J Invest Med* 45:54A, 1997
57. Michel RE, Brown KM, Tally CM, Lertora JLL, George WJ. Novel HPLC method for the quantitation of DDI, DDC, 3TC, D4T and ZDV from small plasma samples. *Clin Pharmacol Ther* 61:220, 1997
58. Comardelle AM, Lertora JJ, Garry RF. Trimethoprim alters ion fluxes in HIV-1-infected human T-lymphoblastoid cells. *J Invest Med* 46:62A, 1998
59. Comardelle AM, Lertora JJ, Garry RF. Trimethoprim-induced changes in ion transport in *Xenopus laevis* oocytes and HIV-1-infected human T-lymphoblastoid cells. *Clin Pharmacol Ther* 63:182, 1998
60. Lertora JLL, Harrison M, Dreisbach AW, Van Dyke R, for the PACTG #274 Study Team. Lack of pharmacokinetic interaction between DDI and ribavirin in HIV infected children. *J Invest Med* 47:106A, 1999
61. Dreisbach AW, Japa S, Kamath B, Mowry SE, Gebrekal A, Tenaglia AN, Lertora JLL. Endstage renal disease (ESRD) reduces hepatic CYP2C9 activity as measured by plasma S/R warfarin ratio. *Clin Pharmacol Ther* 71:9, 2002
62. Dreisbach AW, Japa S, Geberkal AB, Lertora JLL. Prevalence of cytochrome P450 CYP2C9 polymorphisms in African-Americans on hemodialysis. *J Am Soc Nephrol* 13:109P, 2002
63. Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Kamath BL, Rettie AE, Lertora JLL. Cytochrome P4502C9 activity in end-stage renal disease. *Clin Pharmacol Ther* 73(5):475-477, 2003

64. Dreisbach AW, Japa S, Gebrekal AB, Rettie AE, Lertora JLL. Prevalence of cytochrome P450 (CYP2C9) polymorphism in African-Americans on hemodialysis (HD). *J Invest Med* 51:S269, 2003
65. Rasadda S, Japa S, Reddy MN. Methylenetetrahydrofolate reductase (MTHFR) mutation (C677T) in people of Asian Indian descent. *J Invest Med* 51:S259, 2003
66. Mittal SK, Vallabhan TE, Neal JO, Japa S, Clancy DL, Reddy MN. Prevalence and racial distribution of C677T mutation of methylenetetrahydrofolate reductase in patients with known coronary artery disease (CAD). *J Invest Med* 51:S300, 2003
67. Dreisbach AW, Japa S, Sigel A, Fonseca JP, Parenti MB, Farin FM, Rettie AE, Lertora JLL. The prevalence of cytochrome P450 CYP2C8 polymorphisms in African-Americans with endstage renal disease. *J Clin Pharmacol Ther*, Feb. 2004

EDUCATIONAL ARTICLES:

1. Lertora JLL. The digoxin-quinidine interaction. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 1(1):1-3, 1981
2. Lertora JLL. A brief review of marketed beta-adrenergic receptor blocking drugs. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 3(1):1-2, 1983
3. Lertora JLL. Pharmacokinetic considerations in phenytoin therapy. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 4(2):1-2, 1984
4. Lertora JLL. Rational utilization of drug level monitoring. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 4(3):1-3, 1984
5. Lertora JLL. Adverse drug reactions revisited. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 5(1):1-2, 1985
6. Lertora JLL. Drug therapy in the elderly. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 5(4):1-3, 1985
7. Lertora JLL. Amiodarone therapy for refractory ventricular arrhythmias. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 6(3):1-2, 1986
8. Lertora JLL. Basic concepts in pharmacokinetics. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 7(3):1-4, 1987
9. Lertora JLL. Overview of clinical pharmacology. (Syllabus) New Orleans Internal Medicine Board Review Course, Selected Topics, pp 1-11, 1985
10. Lertora JLL. Overview of clinical pharmacology: An update. (Syllabus) New Orleans Internal Medicine Board Review Course, Selected Topics, pp 1-14, 1987
11. Lertora JLL. Adverse drug reactions revisited. Clinical Notes (Michigan Department of Mental Health) 9(1):6-8, 1990
12. Lertora JLL. Prevention of phenytoin toxicity: Pharmacokinetic considerations. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 10(2):1-2, 1990
13. Lertora JLL, Schuler MP, Yates JR. Formulary management program. Pharmacy and Therapeutics Committee Newsletter (Tulane Medical Center) 12(1):1-2, 1992

GRANT SUPPORT:

1. **THE HEMODYNAMIC ACTIONS OF N-ACETYLPROCAINAMIDE**
(NIH Biomedical Research Support Grant RR-03570, Northwestern University Medical School)

Principal Investigator: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 4/1/78 - 3/31/79

2. **FACULTY DEVELOPMENT AWARD IN CLINICAL PHARMACOLOGY**
(Pharmaceutical Manufacturers Association Foundation)

Principal Investigator: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 7/1/78 - 12/31/80

3. **CLINICAL PHARMACOLOGY OF COMMONLY USED DRUGS**
(GM22371 (NIGMS, NIH))

Principal Investigator: Arthur J. Atkinson, Jr., M.D.
Co-Investigators: Juan J. L. Lertora, M.D., Ph.D. (Project Leader)
Jean-Paul Thenot, Ph.D. (Project Leader)
Inclusive Dates: 4/1/79 - 3/31/82

4. **POSTDOCTORAL TRAINING IN CLINICAL PHARMACOLOGY**
(GMO7842 (NIGMS, NIH))

Program Director: Arthur J. Atkinson, Jr., M.D.
Assistant Program Director: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 7/1/80 - 6/30/85

5. **INOTROPIC INTERACTIONS OF ANTIARRHYTHMIC DRUGS AND CARDIAC GLYCOSIDES**
(Biomedical Research Support Grant - Tulane University)

Principal Investigator: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 8/1/81 - 7/31/82

6. **THE INOTROPIC ACTIONS OF N-ACETYLPROCAINAMIDE**
(Edward G. Schlieder Educational Foundation of Louisiana)

Principal Investigator: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 7/1/82 - 6/30/85

GRANT SUPPORT: (cont'd)

7. **THE INOTROPIC ACTIONS OF SOME ANALOGS OF PROCAINAMIDE**
(American Heart Association - Louisiana, Inc.)

Principal Investigator: Juan J. L. Lertora, M.D., Ph.D.
Co-Investigator: Arvind B. Rege, Ph.D.
Inclusive Dates: 7/1/82 - 6/30/83

8. **DEVELOPMENTAL GRANT FOR CLINICAL PHARMACOLOGY UNITS**
(Pharmaceutical Manufacturers Association Foundation)

Principal Investigator: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 7/1/83 - 6/30/86

9. **KINETIC ANALYSIS OF THE INOTROPIC ACTIONS OF DESETHYL-N-ACETYLPROCAINAMIDE**
(Biomedical Research Support Grant - Tulane University)

Principal Investigator: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 9/1/86 - 8/31/87

10. **DOUBLE-BLIND CROSSOVER STUDY OF THE EFFECTS OF DILEVALOL ON THE FOREARM CIRCULATION IN GERIATRIC VOLUNTEERS**
(Schering Corporation)

Co-Principal Investigators: J. David Wallin, M.D.
Juan J. L. Lertora, M.D., Ph.D.
Co-Investigators: George J. Clifton, Ph.D.
Margaret E. Cook, M.D.
Theodore Wang, M.D.
Inclusive Dates: 7/1/86 - 6/30/87

11. **ESTABLISHMENT OF AIDS TREATMENT/EVALUATION CENTER**
(Phase I-II Studies)
(National Institutes of Health - NIAID Contract)

Principal Investigator: Newton E. Hyslop, Jr., M.D.
Co-Investigators: Juan J. L. Lertora, M.D., Ph.D.
(Clinical Pharmacology Team Leader)
William J. George, Ph.D.

(Drug Analysis)
Krishna Agrawal, Ph.D.
(Organic Chemistry - Drug Metabolism)
(Note: Only the Clinical Pharmacology Co-
Investigators are listed for brevity.)

Inclusive Dates: 7/1/87 - 6/30/91

12. **ANTIARRHYTHMIC DRUG COMBINATIONS**

(American Heart Association - Louisiana, Inc.)

Principal Investigator: Theodore Wang, M.D.
Co-Investigator: Juan J. L. Lertora, M.D., Ph.D.
Inclusive Dates: 7/1/87 - 6/30/88

13. **DOUBLE-BLIND STUDY OF THE EFFECT OF CELIPROLOL, ATENOLOL, DILTIAZEM
AND PLACEBO ON FOREARM BLOOD FLOW AND VASCULAR RESISTANCE IN
HYPERTENSIVE PATIENTS**

(Rorer Central Research)

Co-Principal Investigators: F. Gilbert McMahon, M.D.
Juan J. L. Lertora, M.D., Ph.D.
Co-Investigators: Ramon Vargas, M.D.
Theodore Wang, M.D.
Fayez Hadidi, M.D.
Inclusive Dates: 7/1/87 - 6/30/88

14. **NOVEL APPROACHES TO ANTIVIRAL CHEMOTHERAPY**

(National Institutes of Health - NIAID)

Principal Investigator: Krishna C. Agrawal, Ph.D.
Co-Investigators: Juan J. L. Lertora, M.D., Ph.D.
S.R.S. Rangan, Sc.D.
William J. George, Ph.D.
Inclusive Dates: 9/1/87 - 8/31/90

15. **TULANE-LSU ADULT AIDS CLINICAL TRIALS UNIT**

NIH-NIAID

Principal Investigator: Juan J.L. Lertora, M.D., Ph.D.
Co-Investigators: Newton E. Hyslop, Jr., M.D.
Rebecca Clark, M.D. (LSU)
Award Period: 1/1/96-12/31/04

16. **TULANE-LSU/CHARITY GENERAL CLINICAL RESEARCH CENTER**
NCRR/NIH
Principal Investigator: Paul K. Whelton, M.D., M.Sc.
Program Director: Juan J.L. Lertora, M.D., Ph.D.
Award Period: 12/01/01-11/30/06

17. **CLINICAL RESEARCH CURRICULUM AWARD**
NCRR/NIH
Principal Investigator: Roy Weiner, M.D.
Co-Investigator: Juan J.L. Lertora, M.D., Ph.D.
Award Period: 09/01/00-08/30/05

18. **OWH/FDA Pharmacology Research Unit**
Principal Investigator: Juan J.L. Lertora, M.D., Ph.D.
2003-2006
Co-Principal Investigator: Jeanette Magnus, M.D.
Award Period: 2003-2008